Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities

被引：22

作者：

Maher, Lisa ^{[1
,2
]}

White, Bethany ^{[1
,2
]}

Hellard, Margaret ^{[3
]}

Madden, Annie ^{[4
]}

Prins, Maria ^{[5
,6
]}

Kerr, Thomas ^{[7
]}

Page, Kimberly ^{[8
]}

机构：

[1] Univ New S Wales, Ctr Immunol, Viral Hepatitis Epidemiol & Prevent Program, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia

[2] Univ New S Wales, Ctr Immunol, Sch Publ Hlth & Community Med, Darlinghurst, NSW 2010, Australia

[3] Macfarlane Burnet Inst Med Res, Ctr Populat Hlth, Melbourne, Vic 3004, Australia

[4] Australian Intravenous & Injecting League AIVL, Canberra, ACT 2600, Australia

[5] Univ Amsterdam, Acad Med Ctr, NL-1000 CE Amsterdam, Netherlands

[6] GGD Amsterdam Publ Hlth Serv, Dept Res, NL-1000 CE Amsterdam, Netherlands

[7] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada

[8] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA

来源：

VACCINE | 2010年 / 28卷 / 45期

基金：

英国医学研究理事会;

关键词：

Hepatitis C virus; Vaccine; People who inject drugs; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV VACCINE; B VACCINATION; PUBLIC-HEALTH; RISK-FACTORS; COST-EFFECTIVENESS; USERS; INFECTION; HCV; PREVENTION;

D O I：

10.1016/j.vaccine.2010.08.085

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

People who inject drugs (PWID) are at high risk of HCV. Limited evidence of the effectiveness of prevention interventions and low uptake of treatment in this group highlight the need for increased investment in biomedical interventions, notably safe and efficacious vaccines. While several candidates are currently in development, field trials in PWID present challenges, including ethical issues associated with trial literacy, informed consent and standards of care. Significant biological and social factors and differences between HIV and HCV suggest that HCV warrants targeted vaccine preparedness research to lay the groundwork for successful implementation of future trials. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：7273 / 7278

页数：6

共 99 条

[1] High Incidence of Hepatitis C Virus Reinfection in a Cohort of Injecting Drug Users [J].

Aitken, Campbell Kynoch ;

Lewis, Jennifer ;

Tracy, Samantha Lilly ;

Spelman, Timothy ;

Bowden, David Scott ;

Bharadwaj, Mandvi ;

Drummer, Heidi ;

Hetlard, Margaret .

HEPATOLOGY, 2008, 48 (06) :1746-1752

[2] Vaccine immunogenicity in injecting drug users: a systematic review [J].

Baral, Stefan ;

Sherman, Susan G. ;

Millson, Peggy ;

Beyrer, Chris .

LANCET INFECTIOUS DISEASES, 2007, 7 (10) :667-674

[3]

BARNES E, 2010, WHO INITIATIVE VACCI

[4]

Blower S., 2003, AIDS Reviews, V5, P113

[5] HIV vaccine trial preparedness among Spanish-speaking Latinos in the US [J].

Brooks, R. A. ;

Newman, P. A. ;

Duan, N. ;

Ortiz, D. J. .

AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2007, 19 (01) :52-58

[6] Determinants of enrollment in a preventive HIV vaccine trial [J].

Buchbinder, SP ;

Metch, B ;

Holte, SE ;

Scheer, S ;

Coletti, A ;

Vittinghoff, E .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (01) :604-612

[7] Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users [J].

Campbell, Jennifer V. ;

Garfein, Richard S. ;

Thiede, Hanne ;

Hagan, Holly ;

Ouellete, Larry J. ;

Golub, Elizabeth T. ;

Hudson, Sharon M. ;

Ompad, Danielle C. ;

Weinbaum, Cindy .

DRUG AND ALCOHOL DEPENDENCE, 2007, 91 :S64-S72

[8]

CASTELNUOVO E, 2006, COST EFFECTIVENESS T, V10

[9] The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not [J].

Crofts, N ;

Aitken, CK ;

Kaldor, JM .

MEDICAL JOURNAL OF AUSTRALIA, 1999, 170 (05) :220-221

[10] Preventing hepatitis C: 'common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs [J].

Davis, M ;

Rhodes, T ;

Martin, A .

SOCIAL SCIENCE & MEDICINE, 2004, 59 (09) :1807-1818

← 1 2 3 4 5 6 7 8 9 10 →